Reports
Reports
Analysts’ Viewpoint
Rise in prevalence of chronic diseases and increase in incidence of organ failure, which requires organ transplantation, are driving the global organ transplant rejection medication market. Advancements in transplant technology and aging population have led to a surge in the number of transplant procedures, which is driving demand for immunosuppressive drugs. Furthermore, increase in awareness about the benefits of organ transplantation, favorable reimbursement policies, and rise in number of organ donors are propelling market development.
Research & development in new and more effective immunosuppressive drugs offers lucrative opportunities to market players. Companies are focusing on expanding to emerging economies, such as China, India, Brazil, and South Africa, in order to increase market share and revenue.
Organ transplantation has emerged as a promising therapeutic option for patients suffering from organ failure, offering them an extended lifespan and improved quality of life. Despite advances in transplantation techniques and development of immunosuppressive drugs, organ rejection remains a significant concern.
Organ rejection occurs when the recipient's immune system recognizes the transplanted organ as foreign and mounts an attack against it, leading to graft failure. In order to prevent rejection and ensure long-term success of transplantation, patients are required to take immunosuppressive medications that dampen their immune system's response to the transplant.
The organ transplant rejection medication industry includes drugs that are used to prevent and treat organ rejection in transplant recipients. The market has witnessed significant developments in the past few years, including development of newer immunosuppressive agents with improved efficacy and safety profiles, and introduction of novel treatment modalities such as cell-based therapies and gene editing.
Increase in demand for organ transplantation and continued research to advance the field of transplantation medicine are expected to propel global organ transplant rejection medication market value.
Organ failure is a serious medical condition that occurs when one or more vital organs in the body stop functioning correctly. This can happen due to reasons such as illness, injury, or genetic disorders, and is a leading cause of death globally. Incidence of organ failure is increasing due to factors such as an aging population, unhealthy lifestyle choices, and environmental pollution.
Demand for organ transplantation is rising owing to surge in cases of organ failure. In 2017, the World Health Organization (WHO) estimated that 10% of the world's population suffered from chronic kidney disease, putting over 700 million people at risk of developing kidney failure. In the U.S., more than 112,000 people are waiting for an organ transplant, with the majority of them waiting for a kidney transplant.
The Global Observatory on Donation and Transplantation reported that over 140,000 organ transplants were performed worldwide in 2019, with kidneys being the most commonly transplanted organ due to factors such as aging population, diabetes, high blood pressure, obesity, and unhealthy lifestyle factors, such as smoking.
Heart failure is another factor fueling global organ transplant rejection medication market demand. According to WHO, an estimated 17.9 million people succumb to cardiovascular disorders (CVD) each year.
Aging increases the need for health care, as it renders people prone to cardiovascular diseases, such as coronary heart disease, respiratory diseases, such as TB and pneumonia, dental caries, oral cancer, and orthopedic conditions, such as osteoporosis. Rise in prevalence of these diseases is likely to widen the target patient pool for organ transplant.
According to the WHO, the global geriatric population is likely to reach around 2 billion (22% of global population) by 2050, as against 524 million in 2010. Hence, rapidly aging global population is anticipated to augment global organ transplant rejection medication market size.
According to WHO estimates, the geriatric population is expected to rise at a rapid pace in developed countries such as the U.S., the U.K., and Japan. Around 82% of people who succumb to a coronary artery disease are aged 65 years and above.
Access to several diagnostic and treatment services has improved due to favorable healthcare policies and advancements in healthcare facilities in countries such as the U.S., Japan, the U.K., and other countries in Western Europe, which in turn has increased the life expectancy of the population.
Hence, surge in the geriatric population is anticipated to propel global organ transplant rejection medication market development during the forecast period.
In terms of drug class, the calcineurin inhibitors segment accounted for the largest global organ transplant rejection medication market share in 2022. Rise in preference for calcineurin inhibitors due to adequate immunosuppression and less side-effects compared to other classes is likely to propel the segment during the forecast period.
Calcineurin inhibitors (CNIs) have been the cornerstone of immunosuppressive therapy for organ transplant recipients for over 30 years. CNIs, including cyclosporine and tacrolimus, work by inhibiting the activity of calcineurin, a key enzyme in the T-cell signaling pathway that triggers the immune response.
The primary reason for widespread usage of CNIs is their effectiveness in preventing acute rejection of transplanted organs. These significantly reduce the incidence of acute rejection episodes, thereby improving the long-term outcome of organ transplantation. Furthermore, CNIs have been associated with improved graft survival rates compared to other organ transplant immunosuppressants, also known as transplantation immunosuppressants.
Another advantage of CNIs is broad spectrum of activity against both T- and B-cell-mediated immune responses, which makes them useful for a range of organ transplant types. These are also available in various formulations, including oral and injectable versions, making them easy to administer to patients.
Based on transplant type, the kidney transplant segment dominated the global market in 2022. Kidney transplant is the most common type of organ transplant performed globally, with a high success rate. Availability of living donors, including family members and unrelated donors, has increased the number of kidney transplants performed.
Living donor transplants have higher success rates, and the risk of rejection is lower compared to deceased donor transplants. This has contributed to the popularity of kidney transplantation.
Advances in medical technology have made kidney transplantation safer and more successful. New surgical techniques, immunosuppressive drugs, and better diagnostic tools have contributed to rise in successful kidney transplants.
According to WHO, 144,302 transplant surgeries were performed in 2021, with the majority being kidney transplant (92,532), followed by liver transplant (34,694), heart transplant (8,409), lung transplant (6,470), pancreas transplant (2,025), and small bowel transplant (172).
In terms of distribution channel, the retail pharmacies segment accounted for the largest share of the global market 2022.
Several patients prefer retail pharmacies due to timely availability and convenience in terms of purchase of medications associated with retail pharmacies. Rise in number of patients opting for retail pharmacies due to large number of product brands available at discounted prices is likely to drive the segment during the forecast period.
Staff at retail pharmacies is trained and knowledgeable about medications, providing patients with advice and information about their prescriptions. These pharmacies often have established relationships with healthcare providers and insurance companies, facilitating smooth processing of prescriptions and insurance claims.
Retail pharmacies can benefit from economies of scale by purchasing medications in bulk, which can translate into lower prices for patients.
According to organ transplant rejection medication market trends, North America dominated the global industry in 2022. This is ascribed to presence of large number of living as well as deceased donors and better organ-preserving practices in the region.
The market in North America is driven by high incidence of chronic diseases. Rapid adoption of advanced treatment options in the health care sector for treating various diseases is also expected to propel the market in the region during the forecast period. However, high cost and complex procedures are likely to hamper the market in the region during the forecast period.
Increase in the geriatric population is a major concern in Europe, as elderly individuals are more prone to organ dysfunction. The European Commission (Eurostat) has estimated that the geriatric population in Europe could reach 525 million by 2035. Rise in the geriatric population is likely to propel the demand for organ transplant rejection medications in the region during the forecast period.
Developing countries in Asia Pacific are generic-driven markets due to cost-constraints. Increase in competition from generic drugs leading to reduced drug prices and rise in affordability and awareness among patients are expected to propel the organ transplant rejection medications market in the region.
The global market is fragmented, with the presence of large number of players. Companies in the organ transplant rejection medication market are Pfizer, Inc., Astellas Pharma, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Sanofi, Bristol-Myers Squibb Company, GlaxoSmithKline plc, AbbVie, Inc., Hansa Biopharma, WOCKHARDT, Viatris, Inc., Glenmark, Biocon, Hikma Pharmaceuticals plc, Teva Pharmaceutical U.S.A, Inc., and Zydus Pharmaceuticals.
Each of these players has been profiled in the organ transplant rejection medication market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
|
Size in 2022 |
US$ 4.9 Bn |
|
Forecast Value in 2031 |
More than US$ 7.0 Bn |
|
CAGR |
3.9% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global industry was valued at US$ 4.9 Bn in 2022
It is projected to reach more than US$ 7.0 Bn by 2031
The market is anticipated to grow at a CAGR of 3.9% from 2023 to 2031
The kidney segment held more than 60.0% share in 2022
North America is expected to account for largest market share from 2022 to 2031
Pfizer, Inc., Astellas Pharma, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Sanofi, Bristol-Myers Squibb Company, GlaxoSmithKline plc, AbbVie, Inc., Hansa Biopharma, WOCKHARDT, Viatris, Inc., Glenmark, Biocon, Hikma Pharmaceuticals plc, Teva Pharmaceutical U.S.A Inc., and Zydus Pharmaceuticals are the prominent players operating in the market.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Organ Transplant Rejection Medication Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Organ Transplant Rejection Medication Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Current Global Scenario: Organ Donation for Transplantation
5.2. Key Product/Brand Analysis
5.3. Pipeline Analysis
5.4. COVID-19 Impact Analysis
6. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017-2031
6.3.1. Antibodies
6.3.1.1. Thymoglobulin
6.3.1.2. Alemtuzumab
6.3.1.3. Belatacept
6.3.1.4. Muromonab-CD3
6.3.1.5. Basiliximab
6.3.1.6. Eculizumab
6.3.2. Antimetabolites
6.3.2.1. Azathioprine
6.3.2.2. Mycophenolate Mofetil
6.3.2.3. Mycophenolate sodium, MPA
6.3.3. Calcineurin Inhibitors
6.3.3.1. Cyclosporine
6.3.3.2. Tacrolimus
6.3.4. mTOR Inhibitors
6.3.4.1. Sirolimus
6.3.4.2. Everolimus
6.3.5. Steroids
6.3.5.1. Prednisolone
6.3.5.2. Methylprednisolone
6.4. Market Attractiveness Analysis, by Drug Class
7. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Transplant Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Transplant Type, 2017-2031
7.3.1. Kidney
7.3.2. Liver
7.3.3. Heart
7.3.4. Lung
7.3.5. Pancreas
7.3.6. Others
7.4. Market Attractiveness Analysis, by Transplant Type
8. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017-2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Organ Transplant Rejection Medication Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Organ Transplant Rejection Medication Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Class, 2017-2031
10.2.1. Antibodies
10.2.1.1. Thymoglobulin
10.2.1.2. Alemtuzumab
10.2.1.3. Belatacept
10.2.1.4. Muromonab-CD3
10.2.1.5. Basiliximab
10.2.1.6. Eculizumab
10.2.2. Antimetabolites
10.2.2.1. Azathioprine
10.2.2.2. Mycophenolate Mofetil
10.2.2.3. Mycophenolate sodium, MPA
10.2.3. Calcineurin Inhibitors
10.2.3.1. Cyclosporine
10.2.3.2. Tacrolimus
10.2.4. mTOR Inhibitors
10.2.4.1. Sirolimus
10.2.4.2. Everolimus
10.2.5. Steroids
10.2.5.1. Prednisolone
10.2.5.2. Methylprednisolone
10.3. Market Value Forecast, by Transplant Type, 2017-2031
10.3.1. Kidney
10.3.2. Liver
10.3.3. Heart
10.3.4. Lung
10.3.5. Pancreas
10.3.6. Others
10.4. Market Value Forecast, by Distribution Channel, 2017-2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Drug Class
10.6.2. By Transplant Type
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Organ Transplant Rejection Medication Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Class, 2017-2031
11.2.1. Antibodies
11.2.1.1. Thymoglobulin
11.2.1.2. Alemtuzumab
11.2.1.3. Belatacept
11.2.1.4. Muromonab-CD3
11.2.1.5. Basiliximab
11.2.1.6. Eculizumab
11.2.2. Antimetabolites
11.2.2.1. Azathioprine
11.2.2.2. Mycophenolate Mofetil
11.2.2.3. Mycophenolate sodium, MPA
11.2.3. Calcineurin Inhibitors
11.2.3.1. Cyclosporine
11.2.3.2. Tacrolimus
11.2.4. mTOR Inhibitors
11.2.4.1. Sirolimus
11.2.4.2. Everolimus
11.2.5. Steroids
11.2.5.1. Prednisolone
11.2.5.2. Methylprednisolone
11.3. Market Value Forecast, by Transplant Type, 2017-2031
11.3.1. Kidney
11.3.2. Liver
11.3.3. Heart
11.3.4. Lung
11.3.5. Pancreas
11.3.6. Others
11.4. Market Value Forecast, by Distribution Channel, 2017-2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Drug Class
11.6.2. By Transplant Type
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Organ Transplant Rejection Medication Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017-2031
12.2.1. Antibodies
12.2.1.1. Thymoglobulin
12.2.1.2. Alemtuzumab
12.2.1.3. Belatacept
12.2.1.4. Muromonab-CD3
12.2.1.5. Basiliximab
12.2.1.6. Eculizumab
12.2.2. Antimetabolites
12.2.2.1. Azathioprine
12.2.2.2. Mycophenolate Mofetil
12.2.2.3. Mycophenolate sodium, MPA
12.2.3. Calcineurin Inhibitors
12.2.3.1. Cyclosporine
12.2.3.2. Tacrolimus
12.2.4. mTOR Inhibitors
12.2.4.1. Sirolimus
12.2.4.2. Everolimus
12.2.5. Steroids
12.2.5.1. Prednisolone
12.2.5.2. Methylprednisolone
12.3. Market Value Forecast, by Transplant Type, 2017-2031
12.3.1. Kidney
12.3.2. Liver
12.3.3. Heart
12.3.4. Lung
12.3.5. Pancreas
12.3.6. Others
12.4. Market Value Forecast, by Distribution Channel, 2017-2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Drug Class
12.6.2. By Transplant Type
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Organ Transplant Rejection Medication Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017-2031
13.2.1. Antibodies
13.2.1.1. Thymoglobulin
13.2.1.2. Alemtuzumab
13.2.1.3. Belatacept
13.2.1.4. Muromonab-CD3
13.2.1.5. Basiliximab
13.2.1.6. Eculizumab
13.2.2. Antimetabolites
13.2.2.1. Azathioprine
13.2.2.2. Mycophenolate Mofetil
13.2.2.3. Mycophenolate sodium, MPA
13.2.3. Calcineurin Inhibitors
13.2.3.1. Cyclosporine
13.2.3.2. Tacrolimus
13.2.4. mTOR Inhibitors
13.2.4.1. Sirolimus
13.2.4.2. Everolimus
13.2.5. Steroids
13.2.5.1. Prednisolone
13.2.5.2. Methylprednisolone
13.3. Market Value Forecast, by Transplant Type, 2017-2031
13.3.1. Kidney
13.3.2. Liver
13.3.3. Heart
13.3.4. Lung
13.3.5. Pancreas
13.3.6. Others
13.4. Market Value Forecast, by Distribution Channel, 2017-2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Drug Class
13.6.2. By Transplant Type
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Organ Transplant Rejection Medication Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017-2031
14.2.1. Antibodies
14.2.1.1. Thymoglobulin
14.2.1.2. Alemtuzumab
14.2.1.3. Belatacept
14.2.1.4. Muromonab-CD3
14.2.1.5. Basiliximab
14.2.1.6. Eculizumab
14.2.2. Antimetabolites
14.2.2.1. Azathioprine
14.2.2.2. Mycophenolate Mofetil
14.2.2.3. Mycophenolate sodium, MPA
14.2.3. Calcineurin Inhibitors
14.2.3.1. Cyclosporine
14.2.3.2. Tacrolimus
14.2.4. mTOR Inhibitors
14.2.4.1. Sirolimus
14.2.4.2. Everolimus
14.2.5. Steroids
14.2.5.1. Prednisolone
14.2.5.2. Methylprednisolone
14.3. Market Value Forecast, by Transplant Type, 2017-2031
14.3.1. Kidney
14.3.2. Liver
14.3.3. Heart
14.3.4. Lung
14.3.5. Pancreas
14.3.6. Others
14.4. Market Value Forecast, by Distribution Channel, 2017-2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Drug Class
14.6.2. By Transplant Type
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Pfizer, Inc.
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategies
15.3.1.5. Recent Developments
15.3.2. Astellas Pharma, Inc.
15.3.2.1. Company Overview
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. Business Strategies
15.3.2.5. Recent Developments
15.3.3. Novartis AG
15.3.3.1. Company Overview
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. Business Strategies
15.3.3.5. Recent Developments
15.3.4. F. Hoffmann-La Roche Ltd.
15.3.4.1. Company Overview
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. Business Strategies
15.3.4.5. Recent Developments
15.3.5. Sanofi
15.3.5.1. Company Overview
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. Business Strategies
15.3.5.5. Recent Developments
15.3.6. Bristol-Myers Squibb Company
15.3.6.1. Company Overview
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. Business Strategies
15.3.6.5. Recent Developments
15.3.7. GlaxoSmithKline plc
15.3.7.1. Company Overview
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. Business Strategies
15.3.7.5. Recent Developments
15.3.8. AbbVie, Inc.
15.3.8.1. Company Overview
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. Business Strategies
15.3.8.5. Recent Developments
15.3.9. Hansa Biopharma
15.3.9.1. Company Overview
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. Business Strategies
15.3.9.5. Recent Developments
15.3.10. WOCKHARDT
15.3.10.1. Company Overview
15.3.10.2. Financial Overview
15.3.10.2. Product Portfolio
15.3.10.3. Business Strategies
15.3.10.4. Recent Developments
15.3.11. Viatris, Inc.
15.3.11.1. Company Overview
15.3.11.2. Financial Overview
15.3.11.3. Product Portfolio
15.3.11.4. Business Strategies
15.3.11.5. Recent Developments
15.3.12. Glenmark
15.3.12.1. Company Overview
15.3.12.2. Financial Overview
15.3.12.3. Product Portfolio
15.3.12.4. Business Strategies
15.3.12.5. Recent Developments
15.3.13. Biocon
15.3.13.1. Company Overview
15.3.13.2. Financial Overview
15.3.13.3. Product Portfolio
15.3.13.4. Business Strategies
15.3.13.5. Recent Developments
15.3.14. Hikma Pharmaceuticals plc
15.3.14.1. Company Overview
15.3.14.2. Financial Overview
15.3.14.3. Product Portfolio
15.3.14.4. Business Strategies
15.3.14.5. Recent Developments
15.3.15. Teva Pharmaceutical U.S.A Inc.
15.3.15.1. Company Overview
15.3.15.2. Financial Overview
15.3.15.3. Product Portfolio
15.3.15.4. Business Strategies
15.3.15.5. Recent Developments
15.3.16. Zydus Pharmaceuticals, Inc.
15.3.16.1. Company Overview
15.3.16.2. Financial Overview
15.3.16.3. Product Portfolio
15.3.16.4. Business Strategies
15.3.16.5. Recent Developments
List of Tables
Table 01: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 02: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031
Table 03: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031
Table 04: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031
Table 05: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031
Table 06: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031
Table 07: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
Table 08: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 09: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 10: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 11: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031
Table 12: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031
Table 13: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031
Table 14: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031
Table 15: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031
Table 16: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
Table 17: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 18: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country, 2017‒2031
Table 19: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 20: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031
Table 21: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031
Table 22: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031
Table 23: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031
Table 24: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031
Table 25: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
Table 26: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 27: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031
Table 28: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 29: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031
Table 30: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031
Table 31: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031
Table 32: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031
Table 33: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031
Table 34: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
Table 35: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 36: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031
Table 37: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 38: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031
Table 39: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031
Table 40: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031
Table 41: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031
Table 42: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031
Table 43: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
Table 44: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 45: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031
Table 46: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Drug Class, 2017‒2031
Table 47: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antibodies, 2017‒2031
Table 48: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Antimetabolites, 2017‒2031
Table 49: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Calcineurin Inhibitors, 2017‒2031
Table 50: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by mTOR Inhibitors, 2017‒2031
Table 51: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Steroids, 2017‒2031
Table 52: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Transplant Type, 2017-2031
Table 53: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 54: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017‒2031
List of Figures
Figure 01: Global Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Global Organ Transplant Rejection Medications Market Value Share, by Drug Class, 2022
Figure 03: Global Organ Transplant Rejection Medications Market Value Share, by Transplant Type, 2022
Figure 04: Global Organ Transplant Rejection Medications Market Value Share, by Distribution Channel, 2022
Figure 05: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 06: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 07: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Antibodies, 2017‒2031
Figure 08: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Antimetabolites, 2017‒2031
Figure 09: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Calcineurin Inhibitors, 2017‒2031
Figure 10: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by mTOR Inhibitors, 2017‒2031
Figure 11: Global Organ Transplant Rejection Medications Market Value (US$ Mn), by Steroids, 2017‒2031
Figure 12: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
Figure 13: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
Figure 14: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Kidney, 2017-2031
Figure 15: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Liver, 2017-2031
Figure 16: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Heart, 2017-2031
Figure 17: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Lung, 2017-2031
Figure 18: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Pancreas, 2017-2031
Figure 19: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Others, 2017-2031
Figure 20: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 21: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 22: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031
Figure 23: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
Figure 24: Global Organ Transplant Rejection Medications Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
Figure 25: Global Organ Transplant Rejection Medications Market Value Share Analysis, by Region, 2022 and 2031
Figure 26: Global Organ Transplant Rejection Medications Market Attractiveness Analysis, by Region, 2023-2031
Figure 27: North America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
Figure 28: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 29: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 30: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
Figure 31: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
Figure 32: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 33: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 34: North America Organ Transplant Rejection Medications Market Value Share Analysis, by Country, 2022 and 2031
Figure 35: North America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country, 2023-2031
Figure 36: Europe Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
Figure 37: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 38: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 39: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
Figure 40: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
Figure 41: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 42: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 43: Europe Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 44: Europe Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 45: Asia Pacific Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
Figure 46: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 47: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 48: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
Figure 49: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
Figure 50: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 51: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 52: Asia Pacific Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 53: Asia Pacific Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 54: Latin America Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
Figure 55: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 56: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 57: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
Figure 58: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
Figure 59: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 60: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 61: Latin America Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 62: Latin America Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 63: Middle East & Africa Organ Transplant Rejection Medications Market Value (US$ Mn) Forecast, 2017-2031
Figure 64: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Drug Class, 2022 and 2031
Figure 65: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Drug Class, 2023-2031
Figure 66: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Transplant Type, 2022 and 2031
Figure 67: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Transplant Type, 2023-2031
Figure 68: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Distribution Channel, 2022 and 2031
Figure 69: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 70: Middle East & Africa Organ Transplant Rejection Medications Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 71: Middle East & Africa Organ Transplant Rejection Medications Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Organ Transplant Rejection Medication Market